EE495 Threshold Price in the US to Achieve Cost-Effective Use of Molnupiravir and PF-07321332/Ritonavir for the Prevention of Severe COVID-19 in High-Risk Adults

Detalles Bibliográficos
Autores principales: Majda, T, Veenstra, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232762/
http://dx.doi.org/10.1016/j.jval.2022.04.742
_version_ 1784735665154424832
author Majda, T
Veenstra, D
author_facet Majda, T
Veenstra, D
author_sort Majda, T
collection PubMed
description
format Online
Article
Text
id pubmed-9232762
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-92327622022-06-27 EE495 Threshold Price in the US to Achieve Cost-Effective Use of Molnupiravir and PF-07321332/Ritonavir for the Prevention of Severe COVID-19 in High-Risk Adults Majda, T Veenstra, D Value Health Article Published by Elsevier Inc. 2022-07 2022-06-25 /pmc/articles/PMC9232762/ http://dx.doi.org/10.1016/j.jval.2022.04.742 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Majda, T
Veenstra, D
EE495 Threshold Price in the US to Achieve Cost-Effective Use of Molnupiravir and PF-07321332/Ritonavir for the Prevention of Severe COVID-19 in High-Risk Adults
title EE495 Threshold Price in the US to Achieve Cost-Effective Use of Molnupiravir and PF-07321332/Ritonavir for the Prevention of Severe COVID-19 in High-Risk Adults
title_full EE495 Threshold Price in the US to Achieve Cost-Effective Use of Molnupiravir and PF-07321332/Ritonavir for the Prevention of Severe COVID-19 in High-Risk Adults
title_fullStr EE495 Threshold Price in the US to Achieve Cost-Effective Use of Molnupiravir and PF-07321332/Ritonavir for the Prevention of Severe COVID-19 in High-Risk Adults
title_full_unstemmed EE495 Threshold Price in the US to Achieve Cost-Effective Use of Molnupiravir and PF-07321332/Ritonavir for the Prevention of Severe COVID-19 in High-Risk Adults
title_short EE495 Threshold Price in the US to Achieve Cost-Effective Use of Molnupiravir and PF-07321332/Ritonavir for the Prevention of Severe COVID-19 in High-Risk Adults
title_sort ee495 threshold price in the us to achieve cost-effective use of molnupiravir and pf-07321332/ritonavir for the prevention of severe covid-19 in high-risk adults
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232762/
http://dx.doi.org/10.1016/j.jval.2022.04.742
work_keys_str_mv AT majdat ee495thresholdpriceintheustoachievecosteffectiveuseofmolnupiravirandpf07321332ritonavirforthepreventionofseverecovid19inhighriskadults
AT veenstrad ee495thresholdpriceintheustoachievecosteffectiveuseofmolnupiravirandpf07321332ritonavirforthepreventionofseverecovid19inhighriskadults

Ejemplares similares